GlassScriptPhysician profile
Veronica M Chavis
NPI 1144579541
$1,179.21
in general payments reported to CMS, 2019-2025
15 companies · $190 in 2025
The $190 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $350 · 2022: $307 · 2023: $186 · 2024: $147 · 2025: $190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $498 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $497.52 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $331.91 | 2021-2023 | Repatha |
| Novo Nordisk INC | $185.49 | 2021-2024 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $126.42 | 2021-2025 | Verquvo, Belsomra |
| Tolmar, INC. | $108.28 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $90.39 | 2021-2025 | |
| Lilly USA, LLC | $72.24 | 2022-2025 | Zepbound, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $62.23 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $50.57 | 2021 | |
| Esperion Therapeutics, INC. | $43.26 | 2025 | Nexletol |
| Currax Pharmaceuticals LLC | $25.00 | 2023 | Nexletol |
| Inari Medical, INC. | $21.69 | 2022 | |
| Arbor Pharmaceuticals, INC. | $18.08 | 2021 | |
| Verity Pharmaceuticals INC. | $16.90 | 2025 | Tlando |
| Azurity Pharmaceuticals, INC. | $15.52 | 2023 | Adthyza |
| Amarin Pharma, INC. | $11.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veronica Chavis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.